I agree that this site is using cookies. You can find further informations here.
X
Mazières, J
1598  results:
Search for persons X
?
1

Développement d'un parcours de soins pour les patients trai..:

Chesnel, C. ; Perriat, S. ; Puisset, F....
Le Pharmacien Clinicien.  59 (2024)  2 - p. e61-e62 , 2024
Link: https://doi.org/10.1016/..
 
?
2

81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK)..:

Johnson, M.L. ; Ou, S-H.I. ; Felip, E....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S86-S87 , 2023
Link: https://doi.org/10.1016/..
 
?
3

RWD121 Moment Registry (MET NON SMALL CELL CANCER REGISTRY)..:

Thomas, M. ; Christopoulos, P. ; Iams, W.T....
Value in Health.  26 (2023)  12 - p. S527 , 2023
Link: https://doi.org/10.1016/..
 
?
4

121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pemb..:

Peled, N. ; Mazieres, J. ; Kowalski, D.M....
Immuno-Oncology and Technology.  20 (2023)  - p. 100593 , 2023
Link: https://doi.org/10.1016/..
 
?
5

OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with M..:

Kim, T.M. ; Guarneri, V. ; Jye, V.P....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S94 , 2023
Link: https://doi.org/10.1016/..
 
?
6

PPD02.03 Tepotinib in Patients with MET Exon 14 (METex14) S..:

Garassino, M.C. ; Thomas, M. ; Felip, E....
Journal of Thoracic Oncology.  18 (2023)  3 - p. e7-e8 , 2023
Link: https://doi.org/10.1016/..
 
?
7

OC-0261 Impact of radiation to host immune system in patien..:

Pasquier, C. ; Chaltiel, L. ; Massabeau, C....
Radiotherapy and Oncology.  182 (2023)  - p. S198-S199 , 2023
Link: https://doi.org/10.1016/..
 
?
8

10 Osimertinib versus gefitinib followed by osimertinib in ..:

Masip, J. Remon ; Besse, B. ; Aix, S. Ponce...
Journal of Thoracic Oncology.  18 (2023)  4 - p. S35 , 2023
Link: https://doi.org/10.1016/..
 
?
9

OA21.06 ctDNA Dynamics, Prognostic Markers and Resistance M..:

Le, X. ; Garassino, M.C. ; Ahn, M.-J....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S94-S95 , 2023
Link: https://doi.org/10.1016/..
 
?
10

Correction to: Real-world multicentre cohort of first-line ..:

Pons-Tostivint, E. ; Hulo, P. ; Guardiolle, V....
Cancer Immunology, Immunotherapy.  72 (2023)  6 - p. 1891-1892 , 2023
Link: https://doi.org/10.1007/..
 
?
11

Real-world multicentre cohort of first-line pembrolizumab a..:

Pons-Tostivint, E. ; Hulo, P. ; Guardiolle, V....
Cancer Immunology, Immunotherapy.  72 (2023)  6 - p. 1881-1890 , 2023
Link: https://doi.org/10.1007/..
 
?
12

121P Clinical outcomes of compound EGFR mutation in non-sma..:

Brindel, A. ; Anne-Claire, T. ; Praz, J. Ruuth...
ESMO Open.  8 (2023)  1 - p. 101931 , 2023
Link: https://doi.org/10.1016/..
 
?
13

Results of screening in early and advanced thoracic maligna..:

Morfouace, M. ; Novello, S. ; Stevovic, A....
Scientific Reports.  12 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
14

Using Tipifarnib to prevent resistance to targeted therapie..:

Delahaye, C. ; Brachais, M. ; Gence, R....
European Journal of Cancer.  174 (2022)  - p. S55 , 2022
Link: https://doi.org/10.1016/..
 
?
15

IFCT-1502 CLINIVO: real-world evidence of long-term surviva..:

Molinier, O. ; Besse, B. ; Barlesi, F....
ESMO Open.  7 (2022)  1 - p. 100353 , 2022
Link: https://doi.org/10.1016/..
 
1-15